Kornimate/medical-research-clean huggingface dataset:
high-dose multivitamins compared to a placebo in preventing the recurrence of cancer in patients with early stage bladder cancer

Conditions: Bladder Cancer

Summary: rationale: chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. the use of high-dose multivitamins may be an effective way to prevent the recurrence of early stage bladder cancer. it is not yet known whether high-dose vitamins are more effective than no further therapy in decreasing the risk of early-stage bladder cancer. purpose: randomized double-blinded phase iii trial to compare the effectiveness of high-dose multivitamins with a placebo in preventing the recurrence of cancer in patients with early stage bladder cancer.

objective: i. determine whether high dose multivitamins have chemopreventive efficacy beyond standard therapy in reducing the risk of recurrence in patients with resected stage 0 and i (ta, t1, and tis) transitional cell carcinoma of the bladder. outline: this is a randomized, double blind study. patients are randomized to receive multivitamins or placebo orally once daily for 3 years. patients are followed every 3 months for 2 years, then every 6 months for 1 year, and then annually thereafter.

Eligibility criteria:
disease characteristics: histologically confirmed stage 0 and i (ta, t1 or tis) resected transitional cell carcinoma of the bladder no advanced disease or muscle invasion no history of transitional cell carcinoma of the prostate patient characteristics: age: 18 and over performance status: not specified life expectancy: greater than 3 years hematopoietic: wbc at least 3500/mm3 platelet count at least 100,000/mm3 hemoglobin at least 10 g/dl hepatic: bilirubin no greater than 1.5 times upper limit of normal (uln) alkaline phosphatase no greater than 3 times uln sgot no greater than 3 times uln renal: creatinine no greater than 1.5 times uln other: not pregnant or nursing fertile patients must use effective contraception at least 5 years since prior malignancy except nonmetastatic squamous cell or basal cell carcinoma of the skin no history of drug interactions which could affect therapy no immunodeficiency prior concurrent therapy: biologic therapy: prior intravesical bcg required (if t1 or tis pathology and negative cytology pab) chemotherapy: not specified endocrine therapy: not specified radiotherapy: no prior radiotherapy to the pelvis surgery: not specified other: intravesical therapy within 30 days allowed at least 30 days since greater than 2 multivitamins daily

Keywords: recurrent bladder cancer
management of sub-clinical bacteriuria in pregnancy

Conditions: Cystitis; Cystitis;Puerperium; Pyelonephritis

Summary: the purpose of the study is to determine if treatment of pregnant women with urine cultures with a low level of bacteria (less than 100,000 colony forming units (cfu)) may decrease adverse pregnancy outcomes.


Eligibility criteria:
inclusion criteria: * pregnant women who seek prenatal care within the university of texas health system with ut physicians. * urine culture of less than 100,000 cfu exclusion criteria: * less than 18 years of age * risk factors to complicated uti (including but not limited to: diverticula, urolithiasis, renal cysts, indwelling catheter, intermittent catheterization, stent placements, nephrostomy tubes, neurogenic bladder, cystocele, vesicoureteral reflux, ileal conduit) * use of immunosuppressant drugs * abnormalities of the urinary tract (including but not limited to: known ureteric or urethral strictures, tumors of the urinary tract, pelvicalyceal obstruction, congenital anomalies, history of urological procedures) * history of renal disease including renal failure and transplants * urine culture \> 100,000 cfu of any organism
framingham offspring study: psychosocial risk factors

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases; Depression; Atrial Fibrillation

Summary: to examine the relationship between psychosocial characteristics, health behaviors, and the development of coronary heart disease among participants in the framingham offspring study.

design narrative: unique data sets of social, psychological, and behavioral measures were collected at the third examination of the offspring study from 1984 through 1987 (which results in 14 to 17 years of follow-up). hypotheses for this research are focused toward understanding the sex and age differences in the effects these variables have on health endpoints. the research questions involve the prediction of three separate endpoints: incidence of coronary heart disease; the incidence and prognosis of atrial fibrillation; and total mortality. the analyses of psychosocial predictors for these outcomes are divided into four conceptual areas: 1) occupational status and strain, income, and employment status; 2) type a behavior, expressions of anger, hostility, and rate; 3) symptoms of depression, tension, anxiety, and feelings of aloneness; and 4) marital relationships and marital strain. these psychosocial variables will be analyzed jointly with the physiological risk factors collected at the same time to assess independence and interaction of effects. to date these psychosocial data have not been analyzed or published. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
pilot study of how children with asthma exacerbations metabolize prednisone

Conditions: Asthma Exacerbation

Summary: the objective of the investigators pilot study is to assess the pharmacokinetic profile of two corticosteroid drugs, prednisone and prednisolone, in children who present to the pediatric emergency department with an asthma exacerbation. the investigators hypothesis is that the pharmacokinetic profile in this population will be similar to healthy children and adults.

the standard of practice in treating children with asthma exacerbations is to give corticosteroid drugs early in the course of the exacerbation. these drugs decrease symptoms, provide faster time to recovery and improve of quality of life. however, there is 100% variability in a child's response to corticosteroids at a standard dose which is based on primarily on adult studies. the pharmacokinetic analysis or the process by which a drug is metabolized by the body is the first step to determine the proper dose. patients between the ages of 2 and 16 years with asthma exacerbations will be recruited from the pediatric emergency department. after the patients get the drugs, blood samples will be drawn over 8 hours to get the following parameters: maximum concentration reached in the body, the time for the drug to be eliminated from the body, how long the drug stays in the body, how much of the drug is found in the urine after it is given, and concentration of metabolites or breakdown products in urine and blood. these are the parameters needed to make the pharmacokinetic profile and is the first step towards appropriate dosing of these two medications for asthma exacerbations in children.

Eligibility criteria:
inclusion criteria: * patients aged 2 to 16 years * acute asthma exacerbation requiring an oral corticosteroid (either prednisone or prednisolone) * any "reactive airways disease" treated like asthma \[asthma is defined as at least 2 wheezing episodes and/or the patient has been treated with beta agonist and/or inhaled, oral or intravenous corticosteroids for the recurrent episodes of wheezing in the past\] \[acute asthma exacerbation is defined as wheezing episode with any of the following symptoms: tachypnea, dyspnea, use of accessory muscles, or an increased need for short acting beta agonist prior to presentation to ped\] exclusion criteria: * any systemic corticosteroid use within 1 week of presentation to ped * use of any other corticosteroid apart from oral prednisone or prednisolone for the current acute asthma exacerbation * bronchiolitis * underlying chronic medical condition other than asthma (ie: cystic fibrosis, nephrotic syndrome, epilepsy, etc) * liver impairment (including elevated transaminases) * renal impairment * primary or secondary immunodeficiences * concomitant immunosuppressive medication use * ivig use within 4 weeks * need for assisted ventilation

Keywords: asthma pharmacokinetics prednisone prednisolone asthma exacerbation pharmacokinetic profile
social relationships and accelerated aging in hematopoietic cell transplant survivors

Conditions: Hematopoietic and Lymphoid Cell Neoplasm

Summary: this project aims to elucidate the important protective elements of social relationships and identify concrete, modifiable behavioral factors that contribute to biological and phenotypic aging in hematopoietic cell transplantation (hct) survivors and can be used to develop biologically informed interventions to improve quality of life and prolong the healthspan of individuals with accelerated aging.

primary objectives: i. examine associations between social support, strain, and isolation and phenotypic aging over the 1-year recovery period. ii. examine associations between social support, strain, and isolation and biological aging over the 1-year recovery period. iii. test biological aging as a mediator linking social processes and phenotypic aging. exploratory objective: i. test sex differences in aims 1 and 2. outline: adopting a prospective design, participants will complete comprehensive assessments of social processes at 100 days and 1 year after hct that combine reports of social support, strain, and isolation with a naturalistic observation tool, the electronically activated recorder (ear), which captures ambient sound bites to assess social interactions in survivors' daily lives16. at each time point, participants will also provide reports of symptoms to characterize phenotypic aging, including cognitive, physical, and functional complaints, and blood samples to assess biological aging, including cellular senescence, dna damage, sasp, and cellular stress using genome-wide rna sequencing. relevant clinical information that could influence biological aging will also be collected from patients' medical records to consider as covariates.

Eligibility criteria:
inclusion criteria: * aged 18 years and older who are competent to give their informed consent. * ability to read, speak, and understand english. * received a hematopoietic cell transplant within the previous 100 days. exclusion criteria: * less then aged 18 years and older who are competent to give their informed consent. * cannot read, speak, and understand english. * has not received a hematopoietic cell transplant within the previous 100 days.
registry of patients treated by preloaded fenestrated stent-graft designs for complex endovascular aortic procedures

Conditions: Renal Aneurysm; Aneurysm Thoracic; Aneurysm Abdominal

Summary: the aim of the study is to evaluate the outcomes of the preloaded stent-graft design (pld) in the routine treatment of para-renal and thoraco-abdominal aneurysms. results and postoperative events are reported in accordance with the current reporting standards for endovascular aortic repair prepared and revised by the ad hoc committee for standardized reporting practices in vascular surgery of the society for vascular surgery/american association for vascular surgery. the registry will include approximately 300 patients treated from january 2015 to may 2021 (retrospective arm) and june 2021 to june 2023 (perspective arm) for the routine treatment of para-renal and thoraco-abdominal aneurysms. to reach 300 patients, the enrollments can be extended until june 2026.


Eligibility criteria:
inclusion criteria: -patients presenting with an acute (up to two weeks from the onset) and subacute (between 3 and 12 weeks from the onset) type b dissection with a proximal suitable non-dissected landing zone in the aortic arch or descending thoracic aorta (supra-aortic trunks debranching may be employed to obtain an adequate proximal landing zone exclusion criteria: * anatomy requiring sealing in the distal descending thoracic aorta may not be appropriate for a 50 cm sheath due to the risk of it being too short and the graft not reaching the intended landing zone; * celiac trunk or superior mesenteric branch design that makes the graft excessively long; * inability or refusal to give informed consent; * simultaneously participating in another investigative device or drug study; * frank rupture; * systemic infection (eg, sepsis); * allergy to stainless steel, polyester, solder (tin, silver), polypropylene, nitinol, or gold; * untreatable reaction to contrast, which, in the opinion of the investigator, cannot be adequately premedicated.
emotional support and stress management in patients diagnosed with covid-19

Conditions: COVID-19

Summary: the aim of the study is to identify the knowledge that ccspt nurses have in relation to care aimed at addressing anxiety, fear or loneliness and the use they have made of it in the recent crisis. the design of the research/action will also enable the training of the participating professionals to improve nursing care in these areas in the future

this is a cross-sectional descriptive study with a research/action design to be carried out at the consorci corporació sanitària parc taulí (ccspt). the aim of this study is to identify the knowledge that ccspt nurses have in relation to care aimed at coping with anxiety, fear or loneliness and the use that they have made of it in the recent crisis. by its design, the research/action will allow the training of these nurses to improve nursing care of these aspects in the future. this is a population-based study, in which all ccspt nurses who have carried out care work during the covid-19 crisis period will be invited to participate. the variables collected will be age, sex, academic level, usual work shift, care given to reduce anxiety, fear, loneliness, coping style and self-pity. quantitative variables will be described by their mean and standard deviation, while qualitative variables will be described in absolute and relative frequencies. a linear or non-parametric correlation will be made between the score on the self-pity and coping scales and the number of actions identified and/or performed referred to by the nurses and the calculation of the pearson or spearman correlation coefficient, as appropriate. comparison of the number of actions between high activity and low activity (70% cut) coping nurses using the mann-whitney u test

Eligibility criteria:
inclusion criteria: * nurses from any unit of the consortium parc taulí corporation who have been in direct care of patients diagnosed with covid 19 between march 9, 2020 and may 15, 2020 exclusion criteria: -

Keywords: nursing care anxiety loneliness fear education covid-19
volunteers adding life in dementia

Conditions: Dementia; Alzheimer Disease; Behavior

Summary: the objectives of our project are to: 1.) develop a training program and manual for volunteers to implement evidence-based, non-pharmacological interventions for neuropsychiatric symptoms (nps) of dementia in long-term care (ltc) settings; 2.) recruit and train volunteers using the valid program and pilot test the volunteer-led program with 20 individuals with alzheimer's disease and nps in a ltc facility in kingston; and, 3.) evaluate the effects of the valid program on the symptoms of nps, patient quality of life, volunteer's experience, and ltc staff stress.


Eligibility criteria:
inclusion criteria: * diagnosis of alzheimer's disease or related forms of dementia * significant symptoms of agitation as measured by a cohen-mansfield agitation inventory (cmai) total score of \>39 * in nursing home for at least 30 days * presence of a caregiver or substitute decision maker willing to consent to treatment * no changes in psychotropic medications in the 2 weeks preceding enrolment in study exclusion criteria: * depressive symptoms presenting risk * physically aggressive behavior posing safety risk to others * uncontrolled pain * currently receiving palliative care * medically unstable with life expectancy of \< 6 months * currently awaiting transfer to another ltc facility or hospital.
changing patterns of candida infections in urban medical centers

Conditions: Infection; Candida; Non Albicans Species

Summary: the purpose of this study is to determine the changing patterns of infection caused by candida species in urban medical centers and its influence on patient outcomes. a retrospective cohort study design will be employed with the main outcome measure being hospital mortality. secondary outcomes including microbiologic clearance of the infection, duration of hospitalization, and the intensive care unit (icu) length of stay will also be assessed.

the following information that was collected as part of the patient's clinical treatment will be collected: age, sex, occupation, hospital location at the time of positive culture (er, medical ward, icu, etc.), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 30 days of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome, gender, height, weight, ethnicity, and past medical history. we will collect information retrospectively.

Eligibility criteria:
inclusion criteria: * all hospitalized patients with a positive blood culture for candida will be eligible. exclusion criteria: * none

Keywords: infection candida
time restricted feeding on nonalcoholic fatty liver disease

Conditions: Nonalcoholic Fatty Liver Disease

Summary: time restricted feeding (trf) is a novel type of intermittent calorie restriction diet that involves eating a daily period of 8 hours or less. this is a randomized controlled trial to evaluate the effect of time restricted feeding (trf) on hepatic fat contents and cardiometabolic risk factors in obese adults over 6 months compared to continuous energy restriction (cer).


Eligibility criteria:
inclusion criteria: 1. man or women aged≥18 years; 2. subjects with nafld determined by mri (intrahepatic triglyceride content ≥5%); 3. body mass index (bmi)of 28.0 to 45.0 kg/m2; exclusion criteria: 1. history of alcoholic liver disease, chronic viral hepatitis, drug-induced hepatitis, autoimmune hepatitis, cirrhosis, and liver cancer; 2. history of hiv, or active pulmonary tuberculosis; 3. diagnosis of type 1 and type 2 diabetes; 4. history of malignant tumors; 5. serious liver dysfunction or chronic kidney disease (ast or alt \> 3 times the upper limit of normal, or egfr\<30 ml/min/1.73 m2); 6. significant alcohol consumption in the past six months (consumed more than 20 g/day for women or 30 g/day for men); 7. history of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months; 8. history of severe gastrointestinal diseases or gastrointestinal surgery in the past 12 months; 9. history of cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity; 10. being a smoker or having been a smoker in the 3 months prior to their screening visit; 11. taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician; 12. currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) ; 13. women who are pregnant or plan to become pregnant; 14. patients who cannot be followed for 24 months (due to a health situation or migration); 15. patients who are unwilling or unable to give informed consent.

Keywords: nonalcoholic fatty liver disease obesity time restricted feeding calorie restriction
supplementation with pufa´s in obese children

Conditions: Child Obesity; Insulin Resistance; Metabolic Complication

Summary: introduction. insulin resistance (ir) accompanies practically half of children with obesity. this alteration is the border between what can be reversible or permanent. among the comorbidities associated with ir are t2d and cardio and cerebrovascular diseases, which are the leading causes of death in mexico. it has been said that the prevention of obesity rather than its treatment is the way to contain this problem. it has been proposed to supplement obese children with ir with ω-3 polyunsaturated fatty acids (pufa) or ω-9 monounsaturated fatty acids (mufa) to determine their ability to reverse these alterations. objetive. to evaluate the effect of supplementing pufa ω-3, pufa ω-9 or both, on the change in anthropometric and metabolic parameters in obese children with ir. methods. clinical trial, randomized triple-blind, in which obese children with ir participated. intervention. three groups were integrated that received one of the following treatments for three months: group 1: pufa ω-3 1.8 g/day; group 2: pufa ω-3 0.9 g/day + pufa ω-9 0.9 g/day (avocado oil). group 3: mufa ω-9 1.8 g/day. tracing. for 2 more months he continued his clinical surveillance. anthropometric and metabolic profile measurements were made at baseline, 3 and 5 months. throughout the study, all three child groups received nutritional counseling, but no calorie-restricted diets or exercise programs were used.

specific objectives 1. to compare between the study groups, the concentrations of glucose, insulin and homa-ir index, at baseline, at the end of supplementation with pufa ω-3 and pufa ω-9 (3 months) and 2 months after supplementation. the supplementation. 2. to compare between the study groups, the concentrations of total cholesterol, hdl cholesterol, ldl cholesterol and tg at baseline, at the end of supplementation and 2 months after supplementation. 3. to compare between the study groups the change in the percentile values of body mass index (bmi) and waist circumference (wc), between the study groups, at baseline, at the end of supplementation (3 months) and 2 months after supplementation. methods. a randomized, controlled, triple-blind clinical trial was conducted, which included 133 children with obesity (bmi ≥95th percentile) and with ir (homa-ir ≥ 3.0).

Eligibility criteria:
inclusion criteria: * children with obesity (bmi ≥95 pc), according to the cdc reference tables. * homa-ir ≥ 3.0. * that they grant their written consent to participate. exclusion criteria: * patients with any chronic disease. * patients who consume medications that alter their metabolic profile.

Keywords: child obesity insulin resistance metabolic profile pufa ω-3
effect of corn silk tea on hypertension

Conditions: Hypertension

Summary: subjects having hypertension were divided into 3 groups. one control and two experimental who were provided with 2g and 4g of corn silk tea twice per day for 12 weeks.


Eligibility criteria:
inclusion criteria: subjects with hypertension both male and female subjects above age 30 years - exclusion criteria: * subjects below age 30 years pregnant and lactating women subjects with no co morbidities